Biom'Up launches its IPO on the Euronext regulated market in Paris
Saint-Priest, France, September 26, 2017 – Biom’Up, specialist of surgical hemostasis, today announces the launch of its IPO on the Euronext regulated market in Paris.
The Autorité des Marchés Financiers (AMF, the French financial markets authority) granted visa number 17- 508 dated September 25, 2017 for the prospectus relating to the IPO of Biom’Up shares.
Thanks to a world-renowned medical team and its scientific expertise in the field of biopolymers, Biom’Up has developed HEMOBLAST™ Bellows, a best in class hemostatic product that aims to control bleeding during surgical operations (e.g. spine, heart, orthopedic or general surgery); bleeding leads to complications during surgery and lengthens the surgical procedure.